Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bispecific antibodies: advancing precision oncology.
Herrera M, Pretelli G, Desai J, Garralda E, Siu LL, Steiner TM, Au L. Herrera M, et al. Among authors: siu ll. Trends Cancer. 2024 Oct;10(10):893-919. doi: 10.1016/j.trecan.2024.07.002. Epub 2024 Aug 30. Trends Cancer. 2024. PMID: 39214782 Free article. Review.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Among authors: siu ll. Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub 2024 Mar 29. Lancet Oncol. 2024. PMID: 38561010 Clinical Trial.
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies. Smoragiewicz M, et al. Among authors: siu ll. Ann Oncol. 2018 Nov 1;29(11):2175-2182. doi: 10.1093/annonc/mdy398. Ann Oncol. 2018. PMID: 30202892 Free article. Review.
Precision Oncology: A Global Perspective on Implementation and Policy Development.
Horgan D, Tanner M, Aggarwal C, Thomas D, Grover S, Basel-Salmon L, Dienstmann R, Tan TJY, Park WY, Abu Rasheed HM, Siu LL, Ma B, Ortiz-López R, Van den Bulcke M, Taucher SC, Ferris A, Starling N, Malapelle U, Longshore J, Saldaña HAB, Subbiah V. Horgan D, et al. Among authors: siu ll. JCO Glob Oncol. 2025 Jan;11:e2400416. doi: 10.1200/GO-24-00416. Epub 2025 Jan 23. JCO Glob Oncol. 2025. PMID: 39847746 Review.
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
Machtay M, Torres-Saavedra PA, Thorstad W, Nguyen-Tân PF, Siu LL, Holsinger FC, El-Naggar A, Chung C, Cmelak A, Burtness B, Bednarz G, Quon H, Breen SL, Gwede CK, Dicker AP, Yao M, Jordan RC, Dorth J, Lee N, Chan JW, Dunlap N, Bar-Ad V, Stokes WA, Chakravarti A, Sher D, Rao S, Harris J, Yom SS, Le QT; NRG Oncology RTOG 0920 Collaborating Team; TransSCOT Consortium. Machtay M, et al. Among authors: siu ll. J Clin Oncol. 2025 Jan 22:JCO2401829. doi: 10.1200/JCO-24-01829. Online ahead of print. J Clin Oncol. 2025. PMID: 39841939
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA using Structural Variants in Early-Stage Breast Cancer.
Elliott MJ, Howarth K, Main S, Fuentes Antrás J, Echelard P, Dou A, Amir E, Nadler MB, Shah E, Yu C, Bratman S, Bird T, Roh J, de Bruin EC, Rushton C, Birkeälv S, Alcaide M, Oton L, Putcha G, Woodhouse S, Bedard PL, Siu LL, Berman HK, Cescon DW. Elliott MJ, et al. Among authors: siu ll. Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-3472. Online ahead of print. Clin Cancer Res. 2025. PMID: 39785866
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, Balmanoukian AS, Gordon M, Yachnin J, Rottey S, Karydis I, Fisher GA, Schmidt M, Schuler M, Sullivan RJ, Burris HA, Galvao V, Henick BS, Dirix L, Jaeger D, Ott PA, Wong KM, Jerusalem G, Schiza A, Fong L, Steeghs N, Leidner RS, Rittmeyer A, Laurie SA, Gort E, Aljumaily R, Melero I, Sabado RL, Rhee I, Mancuso MR, Muller L, Fine GD, Yadav M, Kim L, Leveque VJP, Robert A, Darwish M, Qi T, Zhu J, Zhang J, Twomey P, Rao GK, Low DW, Petry C, Lo AA, Schartner JM, Delamarre L, Mellman I, Löwer M, Müller F, Derhovanessian E, Cortini A, Manning L, Maurus D, Brachtendorf S, Lörks V, Omokoko T, Godehardt E, Becker D, Hawner C, Wallrapp C, Albrecht C, Kröner C, Tadmor AD, Diekmann J, Vormehr M, Jork A, Paruzynski A, Lang M, Blake J, Hennig O, Kuhn AN, Sahin U, Türeci Ö, Camidge DR. Lopez J, et al. Among authors: siu ll. Nat Med. 2025 Jan;31(1):152-164. doi: 10.1038/s41591-024-03334-7. Epub 2025 Jan 6. Nat Med. 2025. PMID: 39762422 Free PMC article. Clinical Trial.
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.
Luke JJ, Gelmon K, Siu LL, Moreno V, Desai J, Gomez-Roca CA, Carlino MS, Pachynski RK, Cosman R, Chu QS, Damian S, Curigliano G, Tam R, Wang X, Jeyamohan C, Wang L, Zhu L, Santucci-Pereira J, Greenawalt DM, Tabernero J. Luke JJ, et al. Among authors: siu ll. Clin Cancer Res. 2024 Dec 13. doi: 10.1158/1078-0432.CCR-24-0439. Online ahead of print. Clin Cancer Res. 2024. PMID: 39670852
Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients.
Genta S, Araujo DV, Hueniken K, Pipinikas C, Ventura R, Rojas P, Jones G, Butler MO, Saibil SD, Yu C, Easson A, Covelli A, Sauder MB, Fournier C, Saeed Kamil Z, Rogalla P, Arteaga DP, Vornicova O, Spiliopoulou P, Muniz TP, Siu LL, Spreafico A. Genta S, et al. Among authors: siu ll. ESMO Open. 2024 Nov;9(11):103978. doi: 10.1016/j.esmoop.2024.103978. Epub 2024 Nov 16. ESMO Open. 2024. PMID: 39549683 Free PMC article.
435 results